Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
HPC 2017-18
The Best HPC Applications of 2017
10 November 2017
Gemma Church explores applications at the forefront of HPC research
The path to an energy-efficient exascale supercomputer
10 November 2017
Adrian Giordani explores the methods used to accurately measure the performance of supercomputers
AI drives new computing technologies
10 November 2017
Robert Roe looks at advances in AI computing technology
CAE turns to HPC
10 November 2017
Robert Roe interviews Ansys’ Wim Slagter on the value of HPC technology within the CAE market
Firing up a continent
25 October 2017
Nox Moyake describes the process of developing an HPC infrastructure in South Africa
Continental ambitions
25 October 2017
Robert Roe looks at European and North America efforts to establish exascale computing programmes in the next five to seven years
Latest issue
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
